INTRODUCTION: Diabetes, obesity, and metabolic syndrome are highly prevalent in patients with severe mental illness. Psychotropic polypharmacy is becoming increasingly prevalent within the UK. We determined the change in the number of psychotropic medications prescribed over time and trends in weight and fasting blood glucose. METHODS: One hundred ninety-five individuals with schizophrenia and psychosis on the Severe Mental Illness Register in Cheshire, UK, were followed up between 2004 and 2012. Individuals were identified through a semianonymised search of general practitioner registers. RESULTS: The total number of different medications prescribed increased from 140 in 2004 to 226 in 2012 with the mean number of medication groups per pat...
Objective: People with psychotic disorders have an increased metabolic risk and a shortened life exp...
Objective: People with psychotic disorders have an increased metabolic risk and a shortened life exp...
The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease...
INTRODUCTION: Diabetes, obesity, and metabolic syndrome are highly prevalent in patients with severe...
Introduction: Weight gain in the months/years after diagnosis/treatment of severe enduring mental il...
The purpose of this study was to calculate the proportion of patients with schizophrenia receiving p...
Background: People with severe mental illness have a 20-year life-expectancy shortfall. The majority...
Introduction: In spite of recent pharmacologic advances, psychopharmacological treatment of patients...
Purpose: As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of ...
Background: To review evidence of chronic antipsychotic medication and the association with metaboli...
Background: Many reports indicate that the incidence and prevalence of diabetes mellitus is increase...
Introduction: Antipsychotic medication and lifestyle factors are implicated in the high rates of obe...
To compare the prevalence of diabetes in patients with schizophrenia treated at a community mental h...
Introduction: A high prevalence of antipsychotic polypharmacy (APP) and low utilisation of clozapine...
To compare the prevalence of diabetes in patients with schizophrenia treated at a community mental h...
Objective: People with psychotic disorders have an increased metabolic risk and a shortened life exp...
Objective: People with psychotic disorders have an increased metabolic risk and a shortened life exp...
The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease...
INTRODUCTION: Diabetes, obesity, and metabolic syndrome are highly prevalent in patients with severe...
Introduction: Weight gain in the months/years after diagnosis/treatment of severe enduring mental il...
The purpose of this study was to calculate the proportion of patients with schizophrenia receiving p...
Background: People with severe mental illness have a 20-year life-expectancy shortfall. The majority...
Introduction: In spite of recent pharmacologic advances, psychopharmacological treatment of patients...
Purpose: As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of ...
Background: To review evidence of chronic antipsychotic medication and the association with metaboli...
Background: Many reports indicate that the incidence and prevalence of diabetes mellitus is increase...
Introduction: Antipsychotic medication and lifestyle factors are implicated in the high rates of obe...
To compare the prevalence of diabetes in patients with schizophrenia treated at a community mental h...
Introduction: A high prevalence of antipsychotic polypharmacy (APP) and low utilisation of clozapine...
To compare the prevalence of diabetes in patients with schizophrenia treated at a community mental h...
Objective: People with psychotic disorders have an increased metabolic risk and a shortened life exp...
Objective: People with psychotic disorders have an increased metabolic risk and a shortened life exp...
The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease...